Azetukalner Depression Trials Paused After Rare Neuropsychiatric Events
Xenon paused new enrollment in Phase III azetukalner studies for major and bipolar depression after neuropsychiatric adverse events emerged. Current participants continue, but detailed event rates and a causal analysis remain unpublished.
Xenon Pharmaceuticals has temporarily stopped enrolling new patients in late-stage studies of azetukalner for major and bipolar depression after reviewing neuropsychiatric adverse events. People already enrolled will continue treatment, while the company examines whether changing the dose could improve tolerability.
The 30-second summary
- What happened? Xenon voluntarily paused new enrollment across its ongoing psychiatry trials after consulting the independent Data Safety Monitoring Board.
- Why does it matter? The action interrupts Phase III testing of a drug that works through potassium channels rather than the monoamine targets used by many antidepressants.
- What is the catch? Detailed event counts, group-by-group rates and causal analyses have not been published. The pause is temporary and does not affect azetukalner's epilepsy programme.
KEY NUMBER
About 360 people, roughly 80% of the original target, had enrolled in the X-NOVA2 major-depression trial before new recruitment stopped.
What Xenon paused
The decision covers studies in major depressive disorder and bipolar depression. X-NOVA2 is a randomized, placebo-controlled Phase III trial testing 20 milligrams of azetukalner for six weeks. Xenon says its approximately 360 participants provide enough statistical power to complete dosing, unblind the data and report topline results in the first quarter of 2027.
New enrollment is also paused in the wider psychiatry programme, including bipolar-depression studies. Participants already randomized, including those in open-label extensions, remain active. The company says it is considering dose modifications rather than abandoning the programme.
The safety signal is not fully quantified
On a conference call, executives described confusion, speech difficulties, impaired motor coordination and a very small number of events grouped under the broad term psychosis. The chief medical officer put the psychosis rate at around 1% or lower and said the events were brief and reversible. Those details are company-reported; no complete safety table, independent analysis or patient-level record has been released.
Azetukalner opens KV7 potassium channels, allowing potassium to leave neurons and reducing excessive electrical firing. The same mechanism is being developed for seizures. Xenon submitted the drug to the US Food and Drug Administration for focal seizures on September 17, and says the psychiatric pause does not affect that application or ongoing epilepsy trials.
Why an earlier study did not settle the issue
The earlier Phase II X-NOVA trial randomized 168 adults. Its 20-milligram arm produced a clinically meaningful but statistically non-significant advantage over placebo on the primary depression scale at week six. Nervous-system effects such as dizziness, sleepiness and attention disturbance were recorded, but the newly described rare events were not seen in that smaller study.
Larger trials can expose uncommon problems that smaller studies miss. NewTqnia previously covered a cancer trial that ended after an independent safety review. Here, the narrower action is a pause on new enrollment while current participants continue, not termination of the studies.
Before we call this a proven drug risk
- The reported events occurred during the trials, but public data do not establish that azetukalner caused every event.
- The roughly 1% psychosis figure came from a company conference call and lacks a published denominator by study arm.
- No Phase III efficacy result for depression has been reported.
- Azetukalner remains investigational for psychiatric conditions, and the FDA has not approved it for epilepsy either.
- Xenon sponsored the trials and controls the detailed safety dataset.
What happens next
The decisive evidence will be the unblinded X-NOVA2 results, any revised dosing plan and updates to trial registries. Regulators and independent researchers will need enough detail to compare events between drug and placebo groups, judge severity and reversibility, and determine whether a lower or slower dose can preserve any benefit without repeating the signal.
Verified topics and entities
Sources and citations4 sources
External references used to support the reporting in this article.
Published by
NewTqnia Health Desk
An institutional editorial team within NewTqnia
